Uncategorized

Celcuity gains FDA approval for closely-watched breast cancer drug

Published

on

Still, shares fell by nearly 20% after the company revealed a delay in the coming launch of Revtorpyk. Details in the drug’s prescribing information surprised some analysts, too.

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending

Exit mobile version